InspireMD (NSPR, Financial) has reported a modest rise in its first-quarter revenue, reaching $1.529 million compared to $1.511 million in the same period last year. The company has been focusing on expanding the commercial adoption of its technology within its markets, as stated by their CEO. InspireMD is working towards significant future milestones, with a strategic plan for growth. The leadership has emphasized a disciplined approach and has put together a highly skilled commercial team poised to capitalize on the potential FDA PMA approval. The company is optimistic about its trajectory and the opportunities that lie ahead.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 2 analysts, the average target price for InspireMD Inc (NSPR, Financial) is $4.75 with a high estimate of $5.00 and a low estimate of $4.50. The average target implies an upside of 82.69% from the current price of $2.60. More detailed estimate data can be found on the InspireMD Inc (NSPR) Forecast page.
Based on the consensus recommendation from 2 brokerage firms, InspireMD Inc's (NSPR, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for InspireMD Inc (NSPR, Financial) in one year is $0.69, suggesting a downside of 73.46% from the current price of $2.6. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the InspireMD Inc (NSPR) Summary page.
NSPR Key Business Developments
Release Date: March 12, 2025
- Revenue (Q4 2024): $1.95 million, a 10.6% increase year-over-year.
- Full Year Revenue (2024): $7 million, a 13% increase from 2023.
- Gross Profit (Q4 2024): $469,000, a decrease of 7.1% from Q4 2023.
- Gross Margin (Q4 2024): 24.1%, down from 28.7% in Q4 2023.
- Operating Expenses (Q4 2024): $9.8 million, a 55.8% increase from Q4 2023.
- Net Loss (Q4 2024): $9.1 million or $0.19 per share, compared to $5.4 million or $0.16 per share in Q4 2023.
- Gross Margin (Full Year 2024): 21.5%, down from 29.1% in 2023.
- Operating Expenses (Full Year 2024): $35 million, a 52.5% increase from 2023.
- Net Loss (Full Year 2024): $32 million or $0.76 per share, compared to $19.9 million or $0.82 per share in 2023.
- Cash and Cash Equivalents (End of 2024): $34.7 million, down from $39 million at the end of 2023.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- CGuard revenue reached a new quarterly high of $1.95 million in Q4 2024, reflecting a 10.6% growth year-over-year.
- InspireMD Inc (NSPR, Financial) is on track for anticipated US approval and launch of CGuard Prime in the first half of 2025.
- The C-GUARDIANS pivotal clinical trial showed unprecedented low major adverse event rates, supporting the efficacy of CGuard Prime.
- InspireMD Inc (NSPR) has strategically positioned its new headquarters in Miami, Florida, to support the anticipated US launch.
- The company has onboarded over a dozen world-class field sales professionals, preparing for a robust US market entry.
Negative Points
- Gross profit for Q4 2024 decreased by 7.1% to $469,000 due to increased costs of goods sold.
- Gross margin decreased to 24.1% in Q4 2024 from 28.7% in Q4 2023, primarily due to higher material and labor costs.
- Total operating expenses for Q4 2024 increased by 55.8% to $9.8 million, driven by higher salaries and share-based compensation.
- Net loss for Q4 2024 totaled $9.1 million, an increase from a net loss of $5.4 million in the same period in 2023.
- Cash and cash equivalents decreased to $34.7 million as of December 31, 2024, from $39 million the previous year.
